文献速递泌尿生殖与妇科肿瘤放疗

立体定向放疗同步局灶加量治疗中高危局限性前列腺癌:SPARC 2期试验主要结局

Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-03-16

SPARC 2期试验评估射波刀立体定向体部放疗同步整合加量至MRI显示的前列腺内优势病灶,治疗新诊断不利中危至高危局限性前列腺癌。2013至2023年入组20例,中位随访30个月,急性2级及以上泌尿生殖毒性和胃肠道毒性分别为25%和30%,急性3级泌尿生殖毒性1例(5%),至报道时无晚期3级毒性,无生化复发。作者认为该方案耐受性良好,毒性与其他当代SBRT局灶加量试验相当。

要点

  • 前列腺接受36.25 Gy/5次,同步加量至优势病灶最高47.5 Gy,所有患者接受雄激素剥夺治疗。
  • 急性2级及以上泌尿生殖毒性和胃肠道毒性分别为25%和30%,急性3级泌尿生殖毒性1例(5%)。
  • 至报道时无晚期3级泌尿生殖或胃肠道毒性,国际前列腺症状评分和泌尿生活质量评分在6个月恢复至基线。

核心结论

  • 射波刀SBRT给予前列腺36.25 Gy并同步整合加量至优势病灶最高47.5 Gy耐受性良好。
  • 急性和晚期泌尿生殖及胃肠道毒性与其他当代SBRT局灶加量试验和系列相当。

研究设计与样本

  • SPARC为2期试验,入组新诊断、活检证实的不利中危至高危局限性前列腺癌患者,需至少满足以下一项:Gleason≥4+3、MRI定义T3a N0、前列腺特异性抗原≥20,且MRI识别优势病灶不超过2个。
  • 2013至2023年共入组20例,中位随访30个月。
  • 患者接受射波刀SBRT 36.25 Gy/5次隔日照射,在危及器官约束允许下同步加量至优势病灶最高47.5 Gy,所有患者接受雄激素剥夺治疗。
  • 主要结局为急性2级及以上泌尿生殖毒性,采用RTOG评分评估急性和晚期泌尿生殖及胃肠道毒性,并评估生化参数、国际前列腺症状评分、国际勃起功能指数5和EQ-5D生活质量。

主要发现

  • 优势病灶D95剂量中位为47.43 Gy。
  • 急性2级及以上泌尿生殖毒性和胃肠道毒性累积发生率分别为25%和30%。
  • 1例患者发生急性3级泌尿生殖毒性(5%)。
  • 至报道时无晚期3级泌尿生殖或胃肠道毒性。
  • 国际前列腺症状评分和泌尿生活质量评分在6个月恢复至基线,患者报告结局显示12周和1年EQ-5D生活质量评分无显著变化,至报道时无生化复发病例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dose-escalated radiation therapy is associated with better biochemical control at the expense of toxicity. Stereotactic body radiation therapy (SBRT) with dose escalation to the dominant intraprostatic lesion (DIL) provides a logical approach to improve outcomes in high-risk disease while limiting toxicity. This study evaluated the toxicity and quality of life (QoL) with CyberKnife-based SBRT and simultaneous integrated boost in localized prostate cancer. METHODS AND MATERIALS: Eligible participants included newly diagnosed, biopsy-proven unfavorable intermediate- to high-risk localized prostate cancer (at least 1 of the following: Gleason ≥4+3, magnetic resonance imaging(MRI)-defined T3a N0, prostate-specific antigen ≥20) with up to 2 MRI-identified DILs. Participants received 36.25 Gy in 5 fractions on alternative days with a simultaneous boost to DIL up to 47.5 Gy as allowed by organ-at-risk constraints delivered by CyberKnife. All participants received androgen deprivation therapy. The primary outcome measure was acute grade 2+ genitourinary toxicity. Acute and late genitourinary and gastrointestinal toxicity using Radiation Therapy Oncology Group scoring, biochemical parameters, International Prostate Symptom Score, International Index of Erectile Function 5, and EQ-5D QoL outcomes were assessed. RESULTS: Between 2013 and 2023, 20 participants were enrolled with a median follow-up of 30 months. The median D95 dose to DIL was 47.43 Gy. Cumulative acute grade 2+ genitourinary and gastrointestinal toxicity were 25% and 30%, respectively. One patient developed acute grade 3 genitourinary toxicity (5%). There is no late grade 3 genitourinary or gastrointestinal toxicity to date. International Prostate Symptom Score and urinary QoL scores recovered to baseline by 6 months. Patient-reported outcomes showed no significant change in EQ-5D QoL scores at 12 weeks and 1 year. There are no cases of biochemical relapse reported to date. CONCLUSIONS: CyberKnife SBRT-delivered dose of 36.25 Gy to the prostate with a simultaneous integrated boost up to 47.5 Gy is well tolerated. Acute and late genitourinary and gastrointestinal toxicity rates are comparable to other contemporary SBRT trials and series with focal boost.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yasar B, Suh YE, Chapman E, et al. Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 38499253. doi:10.1016/j.ijrobp.2024.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。